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Abstract
In this review we consider the new science of Darwinian medicine. While it has often been said
that evolutionary theory is the glue that holds the disparate branches of biological inquiry together
and gives them direction and purpose, the links to biomedical inquiry have only recently been
articulated in a coherent manner. Our aim in this review is to make clear first of all, how
evolutionary theory is relevant to medicine; and secondly, how the biomedical sciences have
enriched our understanding of evolutionary processes. We will conclude our review with some
observations of the philosophical significance of this interplay between evolutionary theory and the
biomedical sciences.

Background: evolutionary medicine
In this review essay, we consider the interplay between
evolutionary biology, on the one hand, and the biomedical sciences on the other. With certain exceptions (drug
resistance in bacteria being an example) the ties between
evolutionary theory and the biomedical sciences, though
perhaps implicitly recognized, have until relatively
recently, not been coherently articulated. In the last 15
years numerous books and articles have been written
which have attempted to define "the new science of Darwinian medicine." Our aim in this review is thus to delineate the contours of this new branch of biomedical
inquiry, and to draw out some of its philosophical significance.
The relationship between evolutionary biology and the
biomedical sciences has not always been a comfortable
one. Consider comparative physiology – a discipline with
enormous implications for the biomedical sciences, given
the importance of comparative animal studies. Over a
decade ago, Burggrem and Bemis could lament:

Unfortunately comparative physiology traditionally
has been, and continues to be, outside the framework
of contemporary evolutionary biology, often embracing theories, positions or approaches that contemporary morphologists, evolutionary biologists, and
geneticists have abandoned [[1]:193].
The relevance of evolutionary biology to medicine is also
poorly understood by educated members of the public.
Perhaps more disturbing are misunderstandings – and
even a lack of understanding – of the relevance of evolutionary biology for medicine (in theory and in practice)
by medical professionals. As Ewald has observed:
Evolutionary biology is so firmly integrated with the
rest of biology that it is not possible to mark a boundary between them. But modern medicine has been a
peninsula. It is broadly and firmly connected with
most regions of biology. . . but has just a few thin
bridges traversing the gulf to evolutionary biology.
Knowledge about the evolution of antibiotic resist-
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ance is perhaps the best developed bridge between the
disciplines. The discovery of the evolutionary basis for
sickle cell anemia – protection against malaria – is
another [[2]:7].
Ewald continues:
There are probably many reasons for the paucity of
bridges. One stems from the inadequate appreciation
of the pervasiveness of evolutionary principles. From
secondary school through medical school, the fundamental relevance of evolution to all human life has
often been ignored or even suppressed [[2]:7].
We believe it is important for the public, as consumers of
medical services, and for medical practitioners themselves
to have a greater appreciation of the medical implications
of evolutionary biology. At its cutting edge, evolutionary
biology has serious consequences for our understanding
of human health and well-being – consequences that we
ignore at our peril. The issues here will take us into the
doctor's office and the hospital – places a long way away
from the study of fossils of long-dead animals.
Evolutionary biology is a major research specialty in its
own right, and a full review of the matters at hand would
take many volumes. In this essay we focus on some key
areas where evolution has had an impact on our understanding of medical phenomena. We begin with a discussion of some aspects of evolutionary biology.

Evolution: Darwin and beyond
Much biology prior to Darwin was rooted in what may be
termed typological thinking. Species represented fixed types,
and though it was recognized that there could be variants
on the theme of a given type (e.g., domestic dogs), it was
the type itself, not the variants that were of crucial importance. Charles Darwin's great achievement [3] was to turn
this idea on its head by emphasizing the importance of
heritable variation in populations of interest, and to show
how evolutionary mechanisms – natural selection in particular – could not only account for the exquisite adaptations seen in nature – adaptations hitherto attributed to
providential intelligent design – but could also account
for the origin of species – the very types that earlier generations had supposed were fixed and unchanging.
Part of Darwin's aim in his work on natural selection was
to show how it was possible for populations of organisms,
over successive generations, to adapt to problems confronting them in the environments with which they interacted. The classical Darwinian explanation of the
evolution of organismal characteristics known adaptations rests on three basic ideas: (1) Populations of organisms show variation with respect to certain inherited
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characteristics of their members. (2) Individuals in such
variable populations differ in rates of survival and reproduction by virtue of their characteristics, thereby manifesting differential reproductive success; and (3) The heritable
characteristics that contribute to differential reproductive
success will often be inherited by the progeny of successful
individuals. In short, evolution occurs when different
individuals leave behind different numbers of offspring.
Over successive generations, other things being equal,
those characteristics contributing to reproductive success
will manifest themselves as adaptations. Following Sober
[[4]:85], we may define adaptation as follows:
Characteristic c is an adaptation for doing task t in a
population if and only if members of the population
now have c because ancestrally there was selection for
having c and c conferred a fitness advantage because it
performed task t.
It should be noted that organisms have characteristics that
are not, properly speaking, adaptations. Consider your
blood. There was certainly selection for molecules capable
of bearing oxygen. The redness of blood, however, is not
an adaptation. It is simply a consequence of the chemistry
of iron. Similarly, while there has been selection in the
human lineage for large, problem-solving brains, the ability to do differential calculus is not an evolutionary adaptation – it is rather an accidental by-product of selection
for other characteristics.
Darwin himself was aware of the distinction between the
physical, abiotic environment and the biotic environment
(predators, prey, pathogens and parasites, etc.). To this we
may usefully add culture as a dimension of the biotic environment. Culture and a capacity for cultural evolution is
not unique to the human species, yet humans have transformed the environment with which they (and other species) interact – and humans, along with other species of
organisms, have in turn been transformed by the effects of
cultural evolution. Cultural evolution is fast – just consider the changes that occurred in the course of the twentieth century – and it occurs within the lifetimes of longlived organisms such as ourselves. As we will see below,
cultural evolution has important medical implications.
For organisms like us, with relatively long intervals
between generations, rapid evolutionary responses to cultural changes are typically not possible, leading to the
phenomenon of environment discord. For organisms with
much shorter intervals between generations – every
twenty minutes for bacteria such as Staphylococcus aureus,
a major cause of wound infection – rapid, heritable, adaptive responses to such environmental/cultural products as
antibiotics are not only possible, but have become a
major medical problem. This is one of the major reasons
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why an understanding of the evolutionary phenomenon
of host-parasite co-evolution is of vital importance.
Darwin knew virtually nothing about the mechanisms of
inheritance and had precious little knowledge of organic
chemistry (biochemistry was still a largely unformed
intellectual fetus during his lifetime). After 1900, with the
rediscovery of Mendel's insights about the particulate factors involved in the inheritance of characteristics, genetics
emerged as a science in its own right. Of crucial importance here are events occurring from the 1920s through
the 1950s – a period that gave rise to what historians of
biology know as the new evolutionary synthesis. Here ideas
about genetics were fused with ideas about evolution. The
result was that population genetics – especially the study
of the ways in which the relative frequencies of variant
forms of genes (alleles) can change over successive generations – became the corner stone of modern evolutionary
thought. In the course of this intellectual revolution, natural selection (resulting in adaptations) emerges as but
one way in which allele frequencies can change. Other
mechanisms that can shift allele frequencies include random genetic drift, gene flow (the effects of emigration and
immigration), assortative mating, and a variety of linkage
effects. As an understanding of bacterial evolution grew, it
gradually became clear that, in addition to "vertical" gene
transfers across the generations, there are occurrences of
"horizontal" gene transfers (e.g., genes conferring resistance to various drugs can be exchanged between members
of an extant population – there may even be cross-species
horizontal transfers). Such transfers, when they occur, can
permit extremely rapid evolution.
In the last quarter century enormous strides have been
made as evolutionary biologists have learned the need to
fuse their gene-based perspective on evolution with
insights drawn from developmental biology. The resulting
ideas – discussed under the rubric of evolutionary developmental biology – have come to constitute an intellectual revolution in their own right. The results of various
genome projects have shown an enormous genetic similarity between humans, chimps, dogs and mice. At the
level of the genes centrally involved in development (e.g.,
the so-called Hox genes), we are virtually identical. Notwithstanding this, humans and our evolutionary relatives
are clearly very different types of organisms. It is now
beginning to emerge that the key to understanding this
diversity in the face of so much similarity is the study of
gene regulation. For a crude analogy, two identical piano
keyboards can play very different tunes – what matters is
the order and timing with which the keys are played [see
[5-10]].
As evolutionary biology has itself evolved, so too have its
implications for the biomedical sciences and the practice
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of medicine. In the last twenty-five years, a growing
number of evolutionary theorists have started to build
bridges between evolutionary biology and the biomedical
sciences [2,11]. This has culminated in the emergence of a
new discipline called Darwinian Medicine. Darwinian
Medicine is not offered as an alternative to existing
branches of medical inquiry, but rather as a means of
enriching our current understanding of biomedical phenomena [12]. It's a two-way street: as evolution enriches
our understanding of medical phenomena, medicine
enriches our understanding of evolutionary principles.
For example, studies of the nature of humoral immunity
[13,14] as well as cancer [15], have given evolutionary
biologists valuable insights into the mechanisms of adaptive evolution as they shape the fates of populations of
cells in multi-cellular organisms. Some of these examples
are discussed later in this essay. We begin, however, with
examples of the importance of evolutionary ideas to some
of the biomedical sciences.

The biomedical sciences: variation and species
differences
Perhaps the most important consequence, historically, of
a failure to appreciate the implications of evolutionary
biology for the biomedical sciences, lies with the importance that evolutionary biologists place on variation, both
within and between evolving populations of organisms.
As noted by Burggrem and Bemis:
While comparative physiologists have made an art of
avoiding the study of variation, such heritable variation nonetheless is the source of evolutionary changes
in physiology as well as for all other types of characters
[[1]:201].
Ignoring interspecific differences and intraspecific variation, there has been a historic trend for comparative physiologists to revert to pre-evolutionary typological thinking
involving a focus on paradigm "model" species. Again, as
observed by Burggren and Bemis:
Yet the use of "cockroach as insect," "frog as amphibian," or "the turtle as reptile" persists, in spite of clear
evidence of the dangers of this approach. Not surprisingly, this type of comparative physiology has neither
contributed much to evolutionary theories nor drawn
upon them to formulate and test hypotheses in evolutionary physiology [[1]:206].
These problems can also be illustrated by a consideration
of the importance of interspecific variation, intraspecific
variation and gene regulation in the context of pharmacology and toxicology – where the focus is all too often on
"mouse or rat as mammal" – and, in particular, as
"human being."
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In the United States, 14 to 16 million animals are used in
biomedical research each year. The vast majority of mammals (85 to 90 %) employed in such research, aimed at
benefiting humans, are rodents [16]. Primate species are
not a significant part of the total partly because they are
difficult and expensive to house, and partly because, in
the case of such species as gorillas, chimpanzees, and
orangutans, they are close to extinction.
How then, is evolutionary biology relevant to a discussion
of the use of animals in biomedical research aimed at benefiting humans? In terms of the pattern of evolutionary
relationships, the line leading to modern humans seems
to have diverged from the lineage leading to modern
rodents about 70 million years ago, thus representing an
accrual of some140 million years of independent evolution. The lineage leading to modern mice seems to have
diverged from that leading to modern rats some 17 million years ago. It is quite easy to conclude that rats and
mice are more closely related to each other than either is
to humans.
From a genetic point of view, the human genome project
has revealed that the human genome consists of some
30,000 genes. The mouse genome is about the same size
as the human genome [17]. Moreover, reflecting common
ancestry, counterparts (or "orthologs") of many human
genes have been identified in both mice and rats (notwithstanding differences in chromosomal arrangement).
From the standpoint of genetic "base-pair similarity,"
humans, rats, and mice are remarkably similar. But the
devil of genetic differences between individuals of a species, or the genetic differences between members of different species, lies in the details.
Mammals are diploid organisms, which means they have
two sets of chromosomes, one from each parent. Such
chromosomes in a diploid individual are said to be
homologous because that they have the same pattern of
genes along the chromosome. The location of a given gene
on a chromosome is known as its locus. For a given locus,
different versions of a gene – as the alleles – may exist in
an individual (limited to two versions) and/or in a population (two or more versions). Such allelic variation generates variation with respect to the genotypes found in a
population, and is thus a major source of genetic polymorphisms.
Though each individual has two alleles at a given locus
(one from each parent), a large population of such individuals may exhibit several (more than two) alleles for a
given gene. The various relative frequencies of alleles may
be computer for any population. Different alleles typically
have different biological properties. When these properties influence the reproductive success of the organisms
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bearing them, with the effect that different organisms in
the population leave behind different numbers of offspring, then evolution occurs – over successive generations, the frequencies with which given alleles are found
in the population changes. Certainly, allele frequencies
can change for other reasons too, but this need not concern us here.
The main implication of evolutionary biology for our
inquiries is the uncontroversial observation that in natural populations (whether of mice or humans), there is typically variation with respect to the alleles that are present.
But typical laboratory populations of (say) mice are represented by highly inbred strains or varieties. The value of
an inbred strain is supposed to lie in its relative genetic
homogeneity. The hope is that individuals belonging to
such strains should respond similarly when similarly
stimulated (perhaps with drugs or toxins). The use of
highly inbred individuals is a way to control for the real
genetic variation in natural populations which can confound the results and conclusions of laboratory experiments. Thus, the problem of interspecies extrapolation
from rodents to humans (where there are genetic similarities, but not genetic identities) is exacerbated by the fact
that human populations will often not only contain alleles very different from those in rodent populations (where
similar genes can be identified), but will also typically
exhibit allelic variation that is absent in the (homogeneous) laboratory rodent populations used to model them.
The "model" is confounded both by lack of identical (or
even similar) biological properties of alleles and by lack of
overall genetic variation.
Now apply the use of our "model" to a consideration of
the biomedical study of drug and toxin metabolism. The
enzyme system that plays an important role in xenobiotic
(drug and toxin) metabolism is the cytochrome P450 system. Some 500 different P450 enzymes have been characterized by description of their DNA sequences, and
members of a given species may carry 40–50 of these different enzymes [18]. For ease of reference, we will use
"CYPs" as an abbreviation for the Cytochrome P450
enzyme group in the following discussion.
First, some terminology should be introduced. The CYPs
represent a superfamily of genes and each gene (and its
product enzyme) is named according to the similarity of
its DNA sequence to other genes in the superfamily. The
following example will help. Consider CYP 1A2. The first
number designates the family the gene belongs to, which
is determined on the basis of at least 40% sequence similarity. The letter following then designates a subfamily,
determined on the basis of at least 59% sequence similarity. The last number identifies the specific gene (or
enzyme). CYP 1A2 and CYP 3A4, for example, belong to
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different families within the CYP superfamily. By contrast,
CYP 2C9 and CYP 2D6 belong to same family, but different subfamilies. We know also that each gene is composed
of alleles, which may differ, so specific alleles are denoted
by an asterisk and additional number. CYP 2D6*10 refers
to a specific allelic variant (*10) of the CYP2D6 gene and
so on.
Human intraspecific variation
Within biomedical sciences, we all too readily speak of
mice and humans as if all mice and all humans were the
same. For many reasons, this is an error from an evolutionary perspective. In our current example, human CYP
polymorphisms can manifest themselves in the form of
intraspecific (i.e., individual) differences in drug metabolism. Two genes, CYP 2D6 and CYP 2C19 are particularly
important since they affect how people metabolize
approximately 25% of the drugs on the market [19].

Sipes and Gandolfi [20] observed that with respect to the
antihypertensive agent debrisoquine, some 3 to 10 percent of Caucasians are poor metabolizers because they are
homozygous for 2 nonfunctional alleles for CYP 2D6, the
gene source of debrisoquine 4-hydroxylase enzyme. There
appear to be more than 75 allelic variants of CYP 2D6 circulating in human populations [21].
Among these 75 variants, frequencies of the distribution
of alleles vary among different ethnic populations: for
example, individuals homozygous for the *10 allele have
low CYP 2D6 gene activity and are found in nearly 20% of
the Japanese population – a figure that differs from both
Caucasian and Chinese populations [22]. Studies in
molecular genetics indicate that actual cause of reduced
activity of the CYP 2D6 gene is variable and complex.
Causal factors range from single nucleotide polymorphisms in the coding sequences, to effective deletions of
the gene itself, to polymorphisms that affect the splicing
of CYP 2D6 [21]. But on the other side of the coin, there
are rapid metabolizers with high CYP 2D6 gene activity,
related to the fact they possess duplicates of the gene
(some with as many as thirteen copies). High metabolizers with high CYP 2D6 gene activity require more than the
standard doses of drugs to achieve therapeutic responses.
It should be obvious that these important human differences could never have been revealed by nonhuman animal studies.
Consider the metabolism of a specific drug, such as the
antiepileptic drug mephenytoin. More than 20% of the
Japanese population are poor metabolizers (compared to
about 3% of the Caucasian population [20]). Enzymes in
the CYP 2C subfamily have been shown to be responsible
for mephenytoin metabolism, with CYP 2C19 responsible for the main enzyme, (S)-mephenytoin 4'-hydroxlase
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[18]. Poor metabolizers appear to make a stable, but
defective protein [20]. The presence of CYP 2C19*2 and
*3 alleles account for 99% of poor metabolizers within
oriental populations and 87% of Caucasian poor metabolizers.
These examples represent only a minute sample of what is
known about polymorphisms with respect to the specific
enzymes and substrates (drugs, in this case) mentioned.
But they highlight the importance of paying attention to
intraspecific variation when considering metabolic activity. Partly for these reasons, Collins has recently pointed
out:
In the field of metabolism, as well as some segments
of toxicity and efficacy, there has been a major shift
from animal-derived data to human-based data.
Except for comparative studies to assess interspecies
differences, animal studies have declined in importance. Part of this shift is driven be an appreciation for
the uncertainty in cross-species metabolic pathways.
From the practical side, the well-organized, readily
available supply of human tissue has fueled this shift
[[23]:238].
The existence of intraspecific variation is but a foretaste of
the biological problems confronting those who seek to
use animals to model human biomedical phenomena. As
Darwin observed in the Origin of Species:
As each species tends by its geometrical rate of reproduction to increase inordinately in number; and as the
modified descendants of each species will be enabled
to increase by as much as they become more diversified in habits and structure, so as to be able to seize on
many and widely different places in the economy of
nature, there will be a constant tendency of natural
selection to preserve the most divergent offspring of
any one species.
Hence, during a long continued course of modification, the slight differences characteristic of varieties of
the same species, tend to be augmented into the
greater differences characteristic of species of the same
genus [[3]:108].
In other words, one effect of evolutionary processes in the
formation of new species, is essentially to amplify the differences that existed in the varieties belonging to the common ancestor from which the new species descend in the
course of evolutionary time. Thus, further bad news lies in
the fact that interspecific variation is likely to be even
more of a problem for the animal modeler than the
already confounding intraspecific variation we have just
discussed.
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Extrapolation between rodent species
As noted above, rats and mice are more closely related to
each other than either is to humans. While intraspecific
variation is important within rat and mouse (and human)
populations – marked differences exist between different
strains of mice and different strains of rats with respect to
drug metabolism and susceptibility to diseases such as
cancer. Interspecific extrapolation between rats and mice
has proved to be no simple matter – rats are not particularly good models for mice! Thus as Hoffman has
observed:

Correspondence between mouse and rat, the two most
commonly used species in carcinogenicity tests, is not
especially high. For 73 compounds evaluated by Tennant et al., the concordance between mouse and rat
was 67%. Moreover, in an evaluative study by Griesemer and Cueto, only 44 of 98 agents that were carcinogenic in either rats or mice were carcinogenic in both
species [[24]:216].
Extrapolation from rodents to humans
There is an enormous literature on the problems associated with extrapolation from rodents to humans. We will
briefly examine three examples to highlight the difficulties
encountered in any such enterprise.
(a) Cancer
As aptly described in one of the leading textbooks in cell
biology:

The mouse is the most widely used model organism
for the study of cancer, yet the spectrum of cancers
seen in mice differs dramatically from that seen in
humans. The great majority of mouse cancers are sarcomas and leukemias, whereas more than 80% of
human cancers are carcinomas – cancers of epithelia
where rapid cell turnover occurs. Many therapies have
been found to cure cancers in mice; but when the same
treatments are tried in humans they usually fail
[[25]:1347].
There are 26 known human carcinogens (the list of probable carcinogens is somewhat longer). Of these 26 carcinogens, humans are exposed to seven by inhalation. Do
carcinogenicity assays involving rodents convey information about human risk? Two decades ago, Salsburg
observed of the 26 known human carcinogens:
Most of these compounds have been shown to cause
cancer in some animal model. However, many of the
successful animal models involve the production of
injection site sarcomas or the use of species other than
mice or rats. If we restrict attention to long-term feeding studies with mice or rats, only 7 of the 19 human
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non-inhalation carcinogens (36.8%) have been
shown to cause cancer. If we consider long-term feeding or inhalation studies and examine all 26, only 12
(46.2%) have been shown to cause cancer in rats or
mice after chronic exposure by feeding or inhalation.
... On the basis of probability theory we would have
been better off to toss a coin [[26]:64].
Should we be alarmed if a substance induces cancer in rats
or mice? Probably not, especially in view of the fact that
rodents have exhibited carcinogenic responses to 19 out
of 20 substances suspected of being non-carcinogenic in
humans [27]. Thus, the data available today do not support the assumption that these particular animal "models" actually are models for human carcinogenicity
studies.
(b) Diabetes
Differences with respect to gene regulation may be illustrated by the following example. It has been shown that
xenobiotics induce transcription of certain families of
CYPs by activating nuclear receptors. CYP 3As, for example, are regulated by the pregnane X receptor (PXR). Studies have been performed on human and mouse orthologs
of PXR. Moore et al. commented upon the results of these
studies as follows:

However, comparison of PXR from four different species shows that this receptor has diverged considerably
in the course of evolution. The human, rabbit and
rodent PXR are all roughly equally divergent and share
only ~70% amino acid identity. This divergence in
PXR is an important component of cross-species differences in the regulation of CYP3A expression by
xenobiotics [[28]:15126].
Species differences are not just associated with evolution
of the structures of CYP enzymes, they are also associated
with evolution in the molecules that regulate the expressions (on, off, or actual amount) of the genes coding for
those enzymes as well. The regulatory role of PXR is
indeed medically significant. The following provides an
excellent example of this significance.
The CYP 3A family is particularly important in the context
of xenobiotic metabolism because, as Jones et al., have
noted:
The CYP 3A gene products are among the most abundant of the monooxygenases in mammalian liver and
intestine. In humans, CYP 3A4 is involved in the
metabolism of more than 50% of all drugs as well as a
variety of other xenobiotics and endogenous substances, including steroids [[29]:27].
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One drug that is of interest in this regard is troglitazone
(marketed as Rezulin®) and used in the treatment of typeII diabetes. Troglitazone was removed from the market in
the U.S. in March 2000. Despite the fact that it had been
shown to be safe and effective in rodent studies [29], more
than 65 people died (two-thirds were women), and many
other required liver transplants as a result of Rezulin® toxicity. In clinical trials involving a total of 2500 human
subjects, about 2% showed alanine aminotransferase
(ALT) levels more than 3 times the upper limit of normal.
ALT levels this high are an indicator of active liver disease
(see [[30]:114–119] for details of how Rezulin® came to
market on the FDA "fast track").
The class of drugs to which troglitazone belongs was
developed using rodent models of insulin resistance, but
without prior knowledge of the cellular target [29]. It is
now known that troglitazone achieves its therapeutic
effects by binding to the PPARγ nuclear receptor. But the
concentrations required to activate PPARγ also activate the
PXR nuclear receptor in humans – something it did not do
in rats and mice [29]. Thus, one immediate consequence
of this interspecific difference is that human patients taking troglitazone experienced increased CYP 3A4 activity.
Jones et al., comment:
Our data showing that troglitazone activates human
PXR at concentrations similar to those required to activate PPARγ provide an explanation for its interactions
with other drugs, including oral contraceptives. Interestingly, the relative lack of activity of troglitazone on
the mouse or rat PXR may explain why these effects
were not reported in animal toxicology studies. Additional studies will be required to determine whether
PXR also plays a role in the hepatotoxicity observed
with troglitazone. In this regard it is interesting that
that the PXR ligand rifampicin has also been associated with hepatotoxicity in humans [[29]:36].
Recently, it has been argued that the increased CYP 3A4
activity associated with troglitazone activation of human
PXR results in the metabolism of troglitazone to a reactive
quinone which has been hypothesized as the cause of
hepatotoxicity [31]. Examples like this could be multiplied for our discussion here. However, the point is made
that at the molecular level of life there are medically significant differences between species. These differences
may arise from evolved differences in catalytic activity of
enzymes, from evolved differences in the regulation of
gene expression, or even as by-products of interactions
created by the introduction of xenobiotics, never "seen"
by nature or evolution.
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be (and have been) catastrophic. As Goldstein recently
put it in an editorial in the New England Journal of Medicine:
One of the most striking features of modern medicines
is how often they fail to work. Even when they do
work, they are often associated with serious adverse
reactions. Indeed adverse reactions to drugs rank as
one of the leading causes of death and illness in the
developed world [[32]:553].
Endocrinology and Public Policy
Observations of species differences in the context of comparative endocrinology have led at least some observers to
give serious consideration to evolution's consequences.
Thus Hart commented:

It has proved heuristically useful in studies on estrogens. . . to adopt the unifying concept that species differences in estrogen toxicity mirror species differences.
. . in estrogen endocrinology. The poor predictiveness
of animal studies for humans thus becomes comprehensible in terms of interspecies variations in endocrinology [[33]:213].
This matter is very urgent because it has become clear that
a large number of substances in the environment have
impact on estrogenic, androgenic and thyroid hormone
activity. The US Environmental Protection Agency's (EPA)
endocrine disruptor study program will be employed to
examine these issues with a view to human safety and
well-being.
But problems have been uncovered concerning the rodent
strains selected to evaluate the human risk. As Spearow
and Barkley have commented on the results of recent
research:
. . . studies have revealed a tremendous amount of
genetic variation in susceptibility to endocrine disruption by oestrogenic agents between strains of rats and
mice. These studies have shown that the highly prolific, large litter size selected CD-1 mice and SpragueDawley rats most commonly used for product-safety
testing are much more resistant to oestrogenic agents
than other strains examined [[34]:1027].
CD-1 mice are at least 16-fold more resistant than other
strains of mice (including B6) to compounds that cause
inhibition of testis weight, a measurement used as an indicator of androgen activity. CD-1 mice are 126-fold more
resistant than B6 mice to inhibition of sperm maturation
by estradiol [34]; the authors add:

The consequences of the belief that humans and rodents
are the same molecular animal dressed up differently can
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The most favored EPA rodent model for endocrine disruptor testing, the Sprague-Dawley rat, is also more
resistant than other strains to inhibition of testis
weight by (DES) diesthylstiboestrol. Furthermore
Sprague-Dawley rats are highly resistant while Fisher344 rats are highly sensitive to oestradiol, DES or
BisPhenol A induced hyperprolactinaemia, uterine
and vaginal hypertrophy, hyperplasia, mucous secretion and c-Fos induction [[34]:1027].
Since evolution tends to amplify differences between populations after the cessation of gene flow, short of highly
fortuitous convergent evolution (nowhere demonstrated), it is unlikely that interspecific differences will be
less than those observed among different strains of the
same species of rodent. If not highly unlikely, it would, at
the very least, be imprudent to assume in such important
studies.
A good illustration of the problem here lies in the fact that
the rodents selected for the study of endocrine disruption
in humans have been selected for the pragmatic virtue of
large litter sizes. But, as researchers have noted:
We should realize that an animal that has been
selected for high fecundity regulates reproduction
quite differently than unselected individuals. Furthermore, these highly prolific strains tend to be quite precocious, with many "immature" CD-1 females
showing vaginal opening and elevated uterine weights
even in response to the 0 dose control treatment. Such
precocious sexual development and the resulting elevation of ovarian oestrogen production complicates, if
not limits, the use of strains previously selected for
high prolificacy for detecting osestrogenic activities in
intact uterotropic assays [[34]:1028].
Lying at the heart of an evolutionary view of animal populations is variation. Variation exists both within and
between populations. With the cessation of gene flow
between populations, initial variation between ancestral
populations of a given species can be expected to be
amplified in successive generations. Alleles rare in one
such population may become common in another, and so
on.
What then is to be done in the light of observations such
as these? Constructive suggestions for the future course of
medicine already exist that are harmonious with evolutionary theory, and emanate from such branches of biomedical
science
as
pharmacogenetics
and
pharmacogenomics (a branch of pharmacology using
genome-wide techniques to study inherited differences
with respect to drug response). The long-term goal of
pharmacogenomics is that of therapy tailored to an indi-
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vidual patient – therapy that reflects the uniqueness of the
individual as a member of an evolving population. As has
been observed by Evans, et al.,
The potential is enormous for pharmacogenomics to
yield a powerful set of molecular diagnostic methods
that will become routine tools with which clinicians
will select medications and drug doses for individual
patients. . . Genotyping methods are improving so rapidly that it will soon be simple to test for thousands of
single nucleotide polymorphisms in one assay
[[35]:546–547].
What are we to do in the meantime? Population studies
with respect to drug metabolism are already providing
clinically relevant insights. Again, an observation by
Evans, et al.,
. . . a specific genotype may be important in determining the effects of a medication for one population. . .
but not for another; therefore, pharmacogenomic relations must be validated for each therapeutic indication
and in different racial and ethnic groups. Remaining
cognizant of these caveats will help ensure accurate
elucidation of genetic determinants of drug response
and facilitate the translation of pharmacogenomics
into widespread clinical practice [[35]:547].
While the specter of "race-based" medicine is sure to raise
hackles (see relevant discussions [32,36-38]), we already
know of many statistical associations of certain, metabolically significant, allelic variants with certain racial and
ethnic groups. That is to say, two populations may differ
with respect to the relative statistical frequencies of certain
allelic variants. Many of these associations are simply
results of long past events, such as natural or human-created barriers that separated populations. Until such a time
as individualized therapy is possible, matters of ethnicity
ought to be one of the factors taken into account in a
rational discussion of the course of drug therapy, as these
matters currently are recognized and used as a factor in
genetic counseling. The pre-evolutionary, typological
"one therapy fits all," possibly rooted in "Caucasian
(male) as human" model, requires serious critical scrutiny.

Host-parasite co-evolution
Lying at the heart of modern evolutionary theory, as it
impinges directly on medicine, is the concept of host-parasite co-evolution. Indeed, the study of human responses
to infectious, parasitic agents such as bacteria and viruses
is one of the few places where evolutionary theory has had
a major impact on medical theory and practice. As we will
see, however, it has not been "plain sailing" and basic
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misunderstandings of evolution's implications for these
matters are still prevalent.
Paul Ewald has done much to clarify matters in this regard
by critically analyzing the views common, albeit erroneous, in the medical community, including (a) that evolution works for the benefit of the species; and (b) that
parasitism and the resulting diseases are steps on the road
to a state of happy co-existence [2]. According to this
author [2], Rene Dubos claimed in 1965, "Given enough
time a state of peaceful coexistence eventually becomes
established between any host and parasite." In 1972 Lewis
Thomas observed that, "Disease usually represents the
inconclusive negotiations for symbiosis. . . a biological
misrepresentation of borders." [2]. And as late as 1989
Paul Hoeprich could claim, "The ideal of parasitism is
actually commensualism" [2].
The claim that evolution works for the benefit of the species,
though still common outside of evolutionary circles, has
been substantially abandoned by professionals in the
field of evolutionary biology in favor of a thoroughly genocentric view of evolution. As we saw earlier, evolution
occurs because different individuals leave behind different numbers of offspring – offspring carrying a proportion
of alleles identical by descent to those found in the parents. In the case of diploid organisms, the offspring
receive (on average) 50% of their alleles from each parent.
In asexual, clonal species (the proportion will be 100%,
barring horizontal genetic transfers (a non-trivial assumption for bacterial species). One way or another, it is alleles
that travel down the generations.
Evolution has no eye for the future – it does not operate
with a view to the attainment of teleological ends or typological goals. In particular, neither evolution nor the presence of particular characteristics can properly be
characterized as a steady march of progress toward traits
beneficial (in our minds) to the species as a whole. As
Ewald has observed:
Scientist's errors can often be traced to the belief that
natural selection will favor what is best for the longterm stability and survival of the species. In fact natural selection is powerless to favor such long-term survival when it runs counter to short-term competitive
gains. By the time the long-term benefits would be
accrued, the individuals that could provide them
would have vanished from the species by competition.
This misunderstanding owes much to the catchiness of
the phrase "survival of the species," which emphasizes
the species rather than the competitors within the species" [[11]:xiv].
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Such misconceptions are intimately linked to the mistaken view that evolution in the context of host-parasite
relationships is a steady march to a state of "benign coexistence," and hence to mistaken expectations about the
evolution of virulent pathogens and parasites. Again, as
Ewald pointed out:
Natural selection favors characteristics that increase
the passing on of the genes that code for the characteristics. If more rapid replication of a virus inside of a
person leads to a greater passing on of the genes that
code for that rapid replication, then replication rate
will increase even if the more rapid growth of the virus
population within a person causes the person to be
severely ill, or leads to an overall decrease in the numbers of the virus among people, or hastens the eventual extinction of the virus [[2]:4].
This phenomenon can be explored in the context of
within-host selection. Diseases differ with respect to virulence. For most of us the common cold is a nuisance. The
rhinovirus works its evolutionary mischief by keeping its
host mobile – and hence typically in contact with other
susceptible persons who in turn help with the reproduction and dispersal of the virus. By contrast, highly virulent
strains of malaria (e.g., that caused by Plasmodium falciparum), rapidly immobilize the host and kill millions of
human each year.
Since malaria is propagated by biting mosquitoes, the parasite pays no penalty for an immobilized host – especially
one too weak to swat the insect vector. Moreover, simultaneous infection with different strains of P. falciparum with
varying degrees of virulence creates a competitive environment. In such a situation, those strains that attain highest
concentrations in the host's blood in the least amount of
time (thereby wreaking havoc on the host) are those most
likely to be sucked up by biting mosquitoes, who then
spread the progeny of these virulent strains to other susceptible hosts [2]. Another example concerning the illogic
of obligate evolution to a state of benign co-existence, is
provided by Nesse and Williams:
What good would it do a liver fluke to restrain itself so
as not to harm the host if that host is about to die of
shigellosis? The fluke and the shigella are competing
for the same pool of resources within the host, and the
one that most ruthlessly exploits that pool will be the
winner. Likewise, if there is more than one shigella
strain, the one that most effectively converts the host's
resources to its own use will disperse the most progeny
before the host dies [[12]:57].
That millions of parasitic progeny die with the host does
not matter. What matters is differential reproductive suc-
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cess on the part of individual parasites. These are population level phenomena that occur within a single host, but
still result in the passing on of characteristics that aid
effective dispersal of offspring into fresh hosts. A typological goal of benign coexistence simply does not exist in
these instances.
No discussion of host-parasite co-evolution would be
complete without at least a nod in the direction of the evolution of drug resistance by bacteria and viruses. Antibiotics are differential poisons – in this case they are more toxic
to bacteria than they are to us. But bacterial populations
show variation with respect to susceptibility to a given
antibiotic. A given clinical dose of antibiotics should so
damage the bacterial population that the few survivors
should be dealt with by the host's own immune system.
But if the full course of treatment is not followed (or the
patient resorts to unsupervised self-treatment), the antibiotic becomes an agent of selection favoring bacteria
whose genetic constitution can tolerate the antibiotic in
question. The result? Offspring of resistant bacteria will
inherit alleles coding for these characteristics and these
populations will increase. Continued treatment with such
an antibiotic will require higher doses – a process that
cannot continue indefinitely, since patient toxicity will
eventually become an issue. The remedy is to move on to
a new antibiotic, and the whole process may repeat itself,
sometimes with a similar outcome. Unfortunately, the situation with resistant bacteria is even worse, since individual bacteria also can transfer alleles conferring drug
resistance horizontally to other members of their own
population, as well as to members of other bacterial species that may be present in the host.
The situation described here has been observed in viral
populations, with Human Immunodeficiency Virus (HIV)
being a case in point. HIV is an RNA retrovirus that exhibits poor replicative fidelity. In effect, the virus replicates
itself with the aid of the host's own cells, but does so with
such lack of precision that a viral particle may produce
many variants. These variant "offspring" may differ with
respect to susceptibility to the hosts' immune surveillance
or to anti-viral drugs, creating populations of "new" viral
particles with different properties. Nesse and Williams
observe:
A single infection, after years of replication, mutation
and selection, can result in a diverse mixture of competing strains of the virus within a single host. The predominant strains will be those best able to compete
with whatever difficulties must be overcome (e.g., AZT
or other drugs). They will be the ones that most rapidly divert host resources to their own use – in other
words, the most virulent [[12]:57].
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HIV is not the only panic-generating virus in the news.
Much worry is being devoted to avian flu and the possibility of another flu pandemic on the scale of the Spanish flu
of 1918. Some words of evolutionary caution are called
for even here.
The influenza virus particle displays molecules on its surface that can be recognized by the immune system. Different strains of influenza can be identified by their
possession of variants of these molecules. Of particular
interest are H-type molecules (versions of hemagglutinin)
and N-type molecules (versions of neuraminidase). The
Spanish flu of 1918 was caused by an H1N1 virus, in contrast to the avian flu currently in the news, which is an
H5N1 virus. In 1976, a strain of flu with the H1N1 marker
reappeared – causing much panic among flu experts. Was
the panic justified? Arguably not, for as Ewald has
observed:
The H1N1 marker had been present on dangerous
viruses, but there was no reason to think that it made
the viruses dangerous – with its high mutation rate,
the influenza virus can generate tremendous variation
within a matter of weeks while still retaining the
H1N1 marker [[11]:23].
While an obsession with such "marker" molecules can be
highly misleading, the evolutionary questions run to a
deeper level of analysis. We have just seen that parasites
and pathogens differ with respect to strategies for reproduction and dispersal – some keep their hosts mobile,
some succeed by immobilizing their hosts. An evolutionary analysis considers the virus in ecological context. The
conditions that led to the differential reproductive success
of the highly virulent Spanish flu of 1918 were somewhat
unique – in particular, consideration has to be given to
the crowded, unsanitary conditions that existed in the
trenches at the Western front during WW1, along with the
confinement of flu victims to crowded barracks, and subsequently to over-crowded hospitals. The mere existence
of a dangerous virus does not amount to much – unless
conditions exist that favor its differential replicative success and subsequent dispersal. Commenting critically of
approaches adopted by influenza experts, Ewald points
out:
. . . they still confuse the sources of variation – the
mutation and recombination of genes – with the process of evolution by natural selection. And they still
confuse similarity of hemagglutinin and neuraminidase molecules among different virus strains with similarities in the virulence of these strains. . . By failing to
investigate the selective processes that favor increased
or decreased virulence of virus strains, experts still run
the risk of spending too much time and too many
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resources in attempts to block a 1918-type pandemic,
and too little time on how to deal with the more
immediate threats [[11]:25].
The long reach of evolutionary biology into the field of
medicine does not stop here, for evolutionary principles
can be observed with respect to populations of specialized
cells that are found normally in multi-cellular organisms
such as ourselves.

The immune system and cancer
Multi-cellular organisms are composed of cells belonging
to a wide variety of types. Careful studies of the behavior
and dynamics of some of these cellular populations have
revealed that we ourselves are being shaped and influenced by adaptive evolutionary principles during the
course of our individual lives. Here we discuss two examples to illustrate the application of basic evolutionary
principles to these medically significant phenomena.
(a) Humoral Immunity
The immune response concerns the reaction of the body
(self) to invasion by foreign substances (non-self). In the
context of humoral immunity, foreign substances (perhaps viruses or bacteria or parts thereof) known as antigens stimulate B-lymphocyte cells to produce molecules
known as antibodies. Antibodies react with antigens to tag
them for further immunological responses. The details of
the antibody-antigen reaction are instructive for present
purposes.

A specific antibody, carried by a B-lymphocyte, is capable
of "recognizing" (by chemical binding) a limited range of
antigenic molecular shapes. For a given antigen, some
antibodies never bind, some do rarely, and some will bind
to the antigen virtually every time they encounter it. There
is enormous variation and diversity in the antibody population – the system is capable of recognizing more than
108 antigen shapes. Once an antibody binds to an antigen,
the B-cell can receive a second signal from a T cell. This
combination of signals stimulates the particular B-lymphocyte to divide (mitosis) and make daughters of itself.
The proportion of these particular B-cells thus increase in
the lymphocyte population, which then, in turn, create
more of the appropriate antibody. The B-lymphocyte population displays variation and, depending on selective
antigenic binding and signals from other lymphocytes,
differential reproductive success relative to those B-lymphocytes that failed to bind to the current invader.
Some B-lymphocytes become factories for the production
of large numbers of antibodies to fight the current infection. But other successful B-lymphocytes remain in circulation in the body, providing the immune system with a
memory of that particular antigen shape. This phenome-
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non explains why the immune response on subsequent
re-infection is faster than the initial response. These binding characteristics of the descendents of the original successful B-lymphocytes are thus genuine Darwinian
adaptations, in this case for immunological function.
Indeed, Parham has observed:
At some point this century the experimental biologists, in an echo of Henry Ford, divorced themselves
intellectually from the evolutionary biologists. This
artificial and regrettable separation remains with us
today. For the immunologists it was always a sham, for
the very foundations of their subject are built upon
stimulation, selection and adaptive change. Now we
see clearly the immune system for what it is, a vast laboratory of high speed evolution. By recombination,
mutation, insertion and deletion, gene fragments are
packaged by lymphocytes, forming populations of
receptors that compete to grab hold of antigen. Those
that succeed get to reproduce their progeny, if antibodies, submit to further rounds of mutation and selection. There is no going back and the destiny of each
and every immune system is to become unique, the
product of its encounters with antigen and the order in
which they happen. This all happens in somatic tissues, in a time frame of weeks and is perhaps too vulgar, too fast, for traditional tastes to be even called
evolution [[13]:373].
Having a fast, adaptive immune system is clearly advantageous in a world where we are confronted with rapidly
evolving pathogens and parasites. But, as we observed earlier, evolution occurs with no eye to the future. This can
be illustrated through a consideration of the pathological
phenomenon of cancer.
(b) Cancer
In multi-cellular organisms, such as ourselves, there is a
sort of "social contract" between cells of various specialized types (liver cells, kidney cells, etc). These cells are, for
the most part, genetically identical. Kidney cells differ
from liver cells primarily with respect to differential patterns of gene activation, not the genes themselves.
Somatic cells of various specialized types cooperate (and
ultimately perish with the death of the organism) so that
the specialized reproductive cells (gametes) can get genes
identical by descent into the next generation. Cancer cells
can be thought of as outlaws that violate the multi-cellular
social contract. They replicate at the expense of their
neighbors and ultimately at the expense of the organism
bearing them.

The formation of a cancer cell is typically a multi-step
process in which several mutant alleles must be acquired.
The probability of a given cell becoming a cancer cell is
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small, but there are billions of cells – by analogy, the
probability that you win the State lottery is small, but
when millions of tickets have been sold, it is likely that
somebody will win. Cancer cells begin as mutant versions
of healthy cells, and they are cells that have acquired the
ability to activate their own reproduction, producing
almost identical clones. The reproductive process is not
perfect, and the progeny of the initial cancer cell typically
constitute a population of cells displaying variation with
respect to heritable characteristics. The descendents of
these cells themselves acquire mutations and eventually
some may acquire the ability to migrate to new locations,
thereby departing from the confines of their cellular origins. The end result is metastatic cancer. Untreated, and
barring spontaneous remission, unrestrained cellular proliferation, with or without metastasis, typically brings
about the failure of critical organ systems and death.
In the treatment of cancer using chemotherapy, an all too
familiar evolutionary saga plays itself out. Chemotherapeutic agents are differential poisons that target speedily
replicating cancer cells. Unfortunately, they also can affect
other speedily replicating healthy cells (such as epithelial
cells), which is why chemotherapy can have such awful
side-effects. If you are lucky, the chemical agent eliminates
all the cancer cells. Alas, quite often treatment reduces the
cancer cell population to a few hardy survivors while giving the appearance of remission. But this small, now selectively hardy population may gradually repopulate the
patient. The resultant growing population bears the
genetic inheritance that enabled the cancer cells to survive
the initial therapeutic assault – a genetic inheritance
resulting in the evolution of drug resistance. Now the
oncologist is required to try new agents, until they, too,
are rendered ineffective through the adaptive evolution of
populations of the cancer cells in question. As Greaves has
observed:
. . . cancer. . . is a form of evolution played by the same
Darwinian ground rules as apply to evolution in general and particularly for asexually propagating species.
The essential game plan is progressive diversification
by mutation within a clone, coupled with selection of
individual cells on the basis of reproductive and survival fitness, endorsed by their particular gene set. Its
evolution on the fast track [[15]:39].

Conclusion
It is clear that evolutionary biology has an enormous
potential to enrich our understanding of biomedical phenomena. It is also clear that the study of biomedical phenomena can greatly enrich our understanding of
evolutionary processes. These observations should be of
relevance to biological and biomedical investigators and
educators. Moreover, the examples drawn from immunol-
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ogy and oncology show that the human body itself is a
laboratory for fast evolution. This fact has significant philosophical implications for the philosophy of science,
especially as it relates to the nature of explanations in the
biological sciences.
Much of this review has been devoted to ways in which
evolutionary biology can enrich our understanding of
biomedical phenomena. However, the study of biomedical phenomena shows the need to rethink some aspects of
evolutionary biology. Traditional Darwinists draw a sharp
distinction between mechanistic explanations on the one
hand, and evolutionary explanations on the other. Thus,
in dealing with the question, "What is biology?" the great
evolutionary biologist Ernst Mayr observed:
When we try to answer this question, we find that biology actually consists of two rather different fields,
mechanistic (functional) biology and historical biology. Functional biology deals with the physiology of
all activities of living organisms, particularly with all
cellular processes, including those of the genome.
These functional processes ultimately can be
explained purely mechanistically by chemistry and
physics [[39]:24].
But the story does not end so simply; Mayr continues:
The other branch of biology is historical biology. A
knowledge of history is not needed for the explanation
of a purely functional process. However, it is indispensable for the explanation of all aspects of the living
world that involve the dimension of historical time –
in other words, as we now know, all aspects dealing
with evolution. This field is evolutionary biology
[[39]:24].
Mayr observes that the most frequently asked question is
mechanistic (functional) biology is "how?" whereas the
most frequently asked question in evolutionary biology is
"why?" He adds, "To truly appreciate the nature of biology
one must know the remarkable difference between these
two branches of biology" [39].
Focusing their attention on the contours of the new science of Darwinian medicine, traditional Darwinists Nesse
and Williams distinguish between two types of causes that
are medically relevant (and thus require two different
types of causal explanation):
Consider heart attacks. Eating fatty foods and having
genes that predispose to atherosclerosis are major
causes of heart attacks. These are what biologists call
proximate ("near") causes. We are more interested
here in the evolutionary causes that reach further back
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to why we are designed the way we are. In studying
heart attacks, the evolutionist wants to know why natural selection hasn't eliminated the genes that promote fat craving and cholesterol deposition.
Proximate explanations address how the body works
and why some people get a disease and others don't.
Evolutionary explanations show why humans, in general, are susceptible to some diseases and not to others
[[12]:6].
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